Advertisement
Research Article| Volume 30, ISSUE 2, P109-115, July 15, 1991

Smoking and movement disorders in psychiatric patients

DOI:https://doi.org/10.1016/0006-3223(91)90163-G
Smoking and movement disorders in psychiatric patients
Previous ArticleWhere there's smoke … nicotine and psychiatry disorders
Next ArticleEffect of electroconvulsive therapy on serum concentration of alpha-1-acid glycoprotein
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Previous studies have suggested that tardive dyskinesia may occur more frequently in patients who smoke. Further evidence of an interaction between smoking and movement disorders includes the low lifetime exposure to cigarettes found in Parkinson's disease patients. In this study 126 patients with chronic psychiatry illness were blindly evaluated for tardive dyskinesia, neuroleptic-induced parkinsonism, and akathisia. Patients who smoked received significantly higher doses of neuroleptics but did not have significantly more frequent or more severe tardive dyskinesia or parkinsonism. Female smokers did have significantly more akathisia. These results are discussed with regard to interactions between smoking, central dopaminergic tone, and the psychopathology of extrapyramidal syndromes. The effect of smoking on neuroleptic blood levels as well as clinical symptomatology is also discussed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Aceto M.D.
        • Martin B.R.
        Central actions of nicotine.
        Med Res Rev. 1982; 2: 43-62
        • Adler L.
        • Angrist B.
        • Peselow E.
        • et al.
        A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia.
        Br J Psych. 1986; 149: 42-45
        • Balfour D.J.K.
        The effects of nicotine on brain neurotransmitter systems.
        Pharmacol Ther. 1982; 16: 269-282
        • Balfour D.J.K.
        The effects of nicotine on brain neurotransmitter systems.
        in: Balfour D.J.K. Nicotine and the Tobacco Smoking Habit. Pergamon Press, Oxford1984
        • Baumann R.J.
        • Jameson H.D.
        • McKean H.E.
        • et al.
        Cigarette smoking and Parkinson's disease: I. A comparison of cases with matched neighbors.
        Neurology. 1980; 30: 839-843
        • Binder R.L.
        • Kazamatsuri H.
        • Nishimura T.
        • McNeil D.
        Smoking and tardive dyskinesia.
        Biol Psychiatry. 1987; 22: 1280-1282
        • Calne D.B.
        Current views of Parkinson's disease.
        Can J Neurol Sci. 1983; 10: 11-15
        • Chesselet M.F.
        Presynaptic regulation of neurotransmitter release in the brain: facts and hypothesis.
        Neuroscience. 1984; 12: 347-375
        • Clarke P.B.
        • Pert A.
        Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons.
        Brain Res. 1985; 348: 355-358
        • Duvoisin R.C.
        • Eldridge R.
        • Williams A.
        • et al.
        Twin study of Parkinson's disease.
        Neurology. 1981; 31: 77-80
        • Eneroth P.
        • Guxe K.
        • Gustaffson J.A.
        • et al.
        The effect of nicotine on central catecholamine neurons and gonadotropin secretion. II. Inhibitory influence of nicotine on LH, FSH, and prolactin secretion in the ovariectomized female rat and its relation to regional changes in dopamine and noradrenaline levels and turnover.
        Med Biol. 1977; 55: 158
        • Fung Y.H.
        • Lau Y.S.
        Receptor mechanisms of nicotine—Induced locomotor hyperactivity in chronic nicotine-treated rats.
        Eur J Pharmacol. 1988; 152: 263-271
        • Giorguieff-Chesselet M.K.
        • Kemel M.L.
        • Wandscheer D.
        • et al.
        Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: Effect of nicotine in a low concentration.
        Life Sci. 1979; 25: 1257-1262
        • Godwin-Austen R.B.
        • Lee P.N.
        • Marmot M.G.
        • et al.
        Smoking and Parkinson's disease.
        J Neurol Neurosurg Psychiatry. 1982; 45: 577-581
        • Golbe L.I.
        • Cody R.A.
        • Duvoisin R.C.
        Smoking and Parkinson's disease. Search for a dose-response relationship.
        Arch Neurol. 1986; 43: 774-778
        • Hammond C.A.
        Smoking in relation to the death rates of 1 million men and women.
        in: Epidemiologic Approaches to the Study of Cancer and Other Chronic Disease. monograph 19. National Cancer Institute, Bethesda, MD1966: 127-204
        • Henningfield J.E.
        • Goldberg S.R.
        Nicotine as a reinforcer in human subjects and laboratory animals.
        Pharmacol Biochem Behav. 1983; 19: 989-992
        • Jann M.W.
        • Ereshefsky L.
        • Saklad S.R.
        • et al.
        Effects of smoking on fluphenazine clearance in psychiatric inpatients.
        Biol Psychiatry. 1985; 20: 329-352
        • Jeste D.V.
        • Wyatt R.J.
        Understanding and Treating Tardive Dyskinesia.
        Guilford Press, New York1982
        • Kahn H.A.
        The Dorn study of smoking and mortality among U.S. veterans.
        in: Epidemiologic Approaches to the Study of Cancer and Other Chronic Disease. monograph 19. National Cancer Institute, Bethesda, MD1966: 1-125
        • Kessler I.I.
        Parkinson's disease in epidemiologic perspective.
        Adv Neurol. 1978; 19: 355-384
        • Kessler I.I.
        • Diamond E.L.
        Epidemiologic Studies of Parkinson's disease: I. Smoking and Parkinson's disease: A survey and explanatory hypothesis.
        Am J Epidemiol. 1971; 94: 16-25
        • Kirch D.G.
        • Alho A.
        • Wyatt D.J.
        Hypothesis: A nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia.
        Cell Mol Neurobiol. 1988; 3: 285-291
        • Kirch D.G.
        • Gerhardt G.A.
        • Shelton R.C.
        • et al.
        Effect of chronic nicotine administration on monoamine and monoamine metabolite concentration in rat brain.
        Clin Neuropharmacol. 1987; 10: 376-383
        • Lichtensteiger W.
        • Hefti F.
        • Felix D.
        • et al.
        Stimulation of nigrostriatal dopamine neurons by nicotine.
        Neuropharmacology. 1982; 21: 963-968
        • Martilla R.J.
        • Rinne U.K.
        Smoking and Parkinson's disease.
        Acta Neurol Scand. 1980; 62: 322-325
        • Menza M.A.
        • Forman N.E.
        • Goldstein H.S.
        • Golbe L.I.
        Parkinson's disease, personality and dopamine.
        J Neuropsychiatry Clin Neurosci. 1990; 282–287
        • Naguira D.
        • Zunino E.
        • Arqueros L.
        • Viveros O.H.
        Chronic effects of nicotine on catecholamine synthesizing enzymes in rats.
        Eur J Pharmacol. 1978; 47: 227-229
        • Nefzger M.D.
        • Quadfasel F.A.
        • Karl V.C.
        A retrospective study of smoking in Parkinson's disease.
        Am J Epidemiol. 1968; 88: 149-158
        • Oldendorf W.H.
        Lipid solubility and drug penetration in the blood brain barrier.
        in: Proc Soc Exp Biol Med. 147. 1974: 813-815
        • Pomerleau O.F.
        • Pomerleau C.S.
        Neuroregulators and the reinforcement of smoking: Towards a biobehavioral explanation.
        Neurosci Biobehav Rev. 1984; 8: 503-513
        • Simpson G.M.
        • Angus J.W.
        A rating scale for extrapyramidal side effects.
        Acta Psychiatr Scand (Suppl). 1970; 212: 11-17
        • Simpson G.M.
        • Lee J.H.
        • Zoubok B.
        • Gardos G.
        A rating scale for tardive dyskinesia.
        Psychopharmacology. 1979; 64: 171-179
        • Vinarova E.
        • Vinar O.
        • Kalvach Z.
        Smokers need higher doses of neuroleptic drugs.
        Biol Psychiatry. 1984; 19: 1265-1268
        • Ward C.D.
        • Duvoisin R.C.
        • Ince S.E.
        • et al.
        Parkinson's disease in 65 pairs of twins and in a set of quadruplets.
        Neurology. 1983; 33: 815-825
        • Weiner H.L.
        • Lajtha A.
        • Sershen H.
        Dopamine D1 receptor and dopamine D2 receptor binding activity changes during chronic administration of nicotine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
        Neuropharmacology. 1989; 28: 535-537
        • Yassa R.
        • Lal S.
        • Korpassy A.
        • Ally J.
        Nicotine exposure and tardive dyskinesia.
        Biol Psychiatry. 1987; 22: 67-72
        • Youssef H.A.
        • Waddinton J.L.
        Morbidity and mortality in tardive dyskinesia: Associations in chronic schizophrenia.
        Acta Psychiatr Scand. 1987; 75: 74-77

      Article info

      Publication history

      Received in revised form: January 11, 1991
      Received: August 22, 1990

      Identification

      DOI: https://doi.org/10.1016/0006-3223(91)90163-G

      Copyright

      © 1991 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX